Skip to Late-Breaking Abstracts »
All accepted abstracts are available in the Journal for ImmunoTherapy of Cancer (JITC).
Abstract Titles
Poster Presentation Dates
All odd numbered posters will be presented on Wednesday, Nov. 11, from 5:15-5:45 p.m. EST and Friday, Nov. 13, from 4:40-5:10 p.m. EST. Even numbered posters will be presented on Thursday, Nov. 12, from 4:50-5:20 p.m. EST and Saturday, Nov. 14, from 1-1:30 p.m. EST.
Posters will be on display from 8 a.m. on Monday, Nov. 9, until the virtual poster hall closes on December 31, 2020.
| # | Type | Title | Authors | Category | Keywords |
|---|---|---|---|---|---|
| 1 | Poster Presentation | Tumour associated macrophages in HPV-related carcinoma with adenoid cystic like features of the sinonasal tract; a review of three cases | Kasimu U. Adoke, MBBS, FMCPath; Jonathan Madukwe; Faruk Mohammed, Msc; | Biomarkers, Immune Monitoring, and Novel Technologies | Adoptive immunotherapy; Monocyte/Macrophage; Tumor microenvironment; Tumor stroma |
| 30 | Poster Presentation | NLR (Neutrophil Lymphocyte Ratio) and PLR (Platelet Lymphocyte Ratio) Changes as a Predictor of Eventual Treatment Failure and Death on Nivolumab Therapy in Renal Cell Carcinoma | Arnab Basu, MD, MPh, FACP; yash Suri; Lakshminarayan Nandagopal; Mollie R. Deshazo, MD; Lyse A. Norian, PhD; Eddy Yang; | Biomarkers, Immune Monitoring, and Novel Technologies | Checkpoint blockade; Immune monitoring |
| 31 | Oral Presentation | Dynamic change of PD-L1 expression on extracellular vesicles predicts response to immune-checkpoint inhibitors in non-small cell lung cancer patients. | Diego de Miguel Perez, PhD, MSc; Alessandro Russo, MD, PhD; Muthukumar Gunasekaran, PhD; Andrés F. Cardona, MD, PhD; Rena Lapidus, PhD; Brandon Cooper, MSc; Sunjay Kaushal; Christine B. Peterson, PhD; Rivka Colen, MD; Aung Naing, MD, FACP; Vincenzo Adamo, MD, PhD; Christian Rolfo, M.D, PhD, MBA; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Solid tumors; Extracellular vesicles/exosomes |
| 32 | Poster Presentation | C-reactive protein (CRP) as a prognostic biomarker in advanced non-small cell lung cancer treated with Immune Checkpoint Inhibitors. Results from a multi-center international observational study | Abdul Rafeh Naqash, MD; Alessio Cortellini, MD; Emma Mi; Sanna M. Livanainen; Daria Gramenitskaya; James Clark; Kevin O'Brien; Jussi P. Koivunen; Shravanti Macherla; Sweta Jonnalagadda; Shanker R. Polsani; Rahim A. Jiwani, MD; Nitika Sharma, MD; Chipman RG. Stroud; Mahvish Muzaffar, MD; Paul R. Walker, MD; David J. Pinato, MD, MRes, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Checkpoint blockade; Immune suppression; Inflammation; T cell |
| 33 | Poster Presentation | Dynamic monitoring of response to immune checkpoint blockade through deep-learning empowered ultra-sensitive liquid biopsy in melanoma | Adam J. Widman, MD; Cole Khamnei; Jake Bass; Will Liao, PhD; Minita Shah; Nicolas Robine, PhD; Jedd D. Wolchok, MD, PhD; Margaret K. Callahan, MD, PhD; Dan A. Landau, MD, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Checkpoint blockade; Immune monitoring |
| 35 | Poster Presentation | Targeted non-viral integration of large cargo in primary human T cells by CRISPR/Cas9 guided homology mediated end joining | Beau R. Webber, PhD; Matthew J. Johnson, PhD; Nicholas J. Slipek; Walker S. Lahr; Xiaohong Qiu; Blaine Rathmann; Miechaleen D. Diers; Bryce Wick; R. Scott McIvor, PhD; Branden S. Moriarity, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Adoptive immunotherapy; CAR T cells; T cell |
| 36 | Oral Presentation | Molecular events regulating solid tumor cell responses to natural killer cells | Michal Sheffer, PhD; Constantine S. Mitsiades; Michal Sheffer, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers; Immune suppression; NK/NKT cell; Solid tumors; Systems biology; Tumor evasion |
| 44 | Poster Presentation | Body composition may be prognostic and predictive of clinical outcomes in metastatic renal cell carcinoma (mRCC) patients treated with immune checkpoint inhibitors (ICI) | Dylan J. Martini, BA; Dylan J. Martini, BA; T. Anders Olsen, BA; Subir Goyal, Ph.D; Yuan Liu, Ph.D; Sean T. Evans, BS; Benjamin L. Magod, BS; Jacqueline T. Brown, MD; Lauren Yantorni, NP; Greta A. Russler, MSN, FNP-BC; Sarah Caulfield, PharmD, BCOP; Jamie M. Goldman, MD; Bassel Nazha, MD; Wayne B. Harris, MD; Omer Kucuk, MD; Bradley C. Carthon, MD Ph.D; Viraj A. Master, MD Ph.D; Mehmet A. Bilen, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Checkpoint blockade; Clinical study; Metabolism; Solid tumors |
| 45 | Poster Presentation | Body composition as a predictive and prognostic biomarker in advanced urothelial carcinoma (UC) patients treated with immune checkpoint inhibitors (ICI) | Dylan J. Martini, BA; Julie M. Shabto, BA; Subir Goyal, Ph.D; Yuan Liu, Ph.D; T. Anders Olsen, BA; Sean T. Evans, BS; Benjamin L. Magod, BS; Deepak Ravindranathan, MD, MS; Jacqueline T. Brown, MD; Lauren Yantorni, NP; Greta A. Russler, MSN, FNP-BC; Sarah Caulfield, PharmD, BCOP; Jamie M. Goldman, MD; Bassel Nazha, MD; Shreyas S. Joshi, MD, MPH; Haydn T. Kissick, Ph.D; Kenneth Ogan, MD; Wayne B. Harris, MD; Omer Kucuk, MD; Bradley C. Carthon, MD Ph.D; Viraj A. Master, MD Ph.D; Mehmet A. Bilen, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Clinical study; Metabolism; Solid tumors |
| 51 | Poster Presentation | Small cell/lymphohistiocytic morphology is associated with CD8 positivity, retained T cell markers, a trend of decreased PD-L1 expression, but not outcome in adults with ALK+ ALCL | Mahsa Khanlari; Shaoying Li, MD; Roberto N. Miranda, MD; Swaminathan Iyer, MD; Cameron Yin, MD, PhD; Pei Lin, MD; Guilin Tang, MD, PhD; Sergej N. Konoplev, MD, PhD; L. Jeffrey Medeiros, MD; Jie Xu, MD, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody; Epidemiology; Leukemia/Lymphoma; Targeted therapy |
| 53 | Poster Presentation | Predictors of response to Immune checkpoint inhibitor therapy in metastatic solid tumors: Real world evidence | Aasems Jacob, MD; Jianrong Wu, PhD; Jill Kolesar, PharmD; Eric Durbin, MS, DrPH; Aju Mathew, MD, MPH; Susanne M. Arnold, MD; Aman Chauhan, MD; Aasems Jacob, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers; Checkpoint blockade; Clinical study; Immune monitoring; Immune tolerance; Immune toxicity; Solid tumors |
| 63 | Poster Presentation | Microsatellite instability/mismatch repair biomarker testing disparities in patients with advanced colorectal cancer: Implications for immune checkpoint inhibitors | Bryan Iorgulescu, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade |
| 68 | Poster Presentation | The prognostic and predictive implications of the 12-chemokine score in muslce invasive bladder cancer | Roger Li, MD; Logan Zemp, MD; Anders E. Berglund, PhD; Jasreman Dhillon, MD; Ryan Putney, PhD; Youngchul Kim, PhD; Rohit K. Jain, MD; Daniel Grass, MD; Jingsong Zhang, MD, PhD; Michael A. Poch, MD; Julio M. Pow-Sang, MD; Wade J. Sexton, MD; Scott M. Gilbert, MD; Shari A. Pilon-Thomas, PhD; José Conejo-Garcia, MD, PhD; Colin P. Dinney, MD; James J. Mulé, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Checkpoint blockade; Chemokine; Immune contexture; Tumor microenvironment |
| 83 | Poster Presentation | The Prognostic Significance of Peripheral Blood Biomarkers in Patients with Advanced Non-Small Cell Lung Cancer Treated with Pembrolizumab: A Clinical Study | Kira MacDougall, MD; Muhammad Niazi, MD; Jeff Hosry, MD; Sylvester Homsy, MD; Alexander Bershadskiy, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Immune monitoring; Inflammation; Targeted therapy |
| 757 | Poster Presentation | Intratumoral delivery CD40 agonist antibody via novel nanofluidic drug-eluting seed reduced tumor burden of murine pancreatic ductal adenocarcinoma | Hsuan-Chen Liu, PhD; Dixita I. Viswanath; Robin Vander Pol; Corrine Chua; Alessandro Grattoni, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody; Radiotherapy; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 758 | Oral Presentation | Identification of tumor antigen-specific T cells in the peripheral blood of colorectal cancer patients | Emilie Picard, PhD; Alexandrine L. Martel; Alain Simard; Hoang-Thanh Le; Chris P. Verschoor; Grace W. Ma; Graham P. Pawelec, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Clinical study; Immune contexture; Immune monitoring; Solid tumors; T cell; Tumor antigens |
| 759 | Poster Presentation | Development of an implantable artificial lymph node as a therapeutic cancer vaccine | Dixita I. Viswanath, N/A; Hsuan-Chen Liu, PhD; Corrine Ying Xuan Chua, PhD; Alessandro Grattoni, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Cytokine; Dendritic cell; Immune adjuvant; Neoantigens; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Vaccine |
| 760 | Poster Presentation | Trough levels of ipilimumab in serum as a potential predictive biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab | Yoshinobu Koguchi, MD, PhD; Noriko NI. Iwamoto, PhD; Takashi Shimada, PhD; Shu-Ching Chang, PhD; John Cha; Brian D. Piening, PhD; Brendan D. Curti, MD; Walter J. Urba, MD, PhD; William L. Redmond, Ph.D.; | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody; Biomarkers; Checkpoint blockade; Chemokine; Clinical study; Immune monitoring; Proteomics |
| 761 | Poster Presentation | Potential predictive biomarkers of rapid progression and response to anti-PD1 treatment by gene profiling analysis in metastatic melanoma patients. | Maria Grazia Vitale, MD; Domenico Mallardo, MD; Antonio M. Grimaldi, MD; Ncholas Bayless; Mariaelena Capone, MD; Gabriele Madonna, MS; Vito Vanella, MD; Lucia Festino; Claudia Trojaniello; Marcello Curvietto; Luigi Scarpato; Sarah E. Warren, PhD; SuFey Ong; Ernesta Cavalcanti; Corrado Caracò; Alessandra Cesaro; Ester Simeone, MD; Paolo A. Ascierto, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Gene expression; Immune contexture; Immune suppression; Solid tumors; Tumor evasion |
| 762 | Oral Presentation | A combination of functional biomarkers improves identification of the tumor-specific reactive T cell repertoire | Arianna Draghi, MD; Katja Harbst; Inge Svane, MD; Marco Donia, MD, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Tumor infiltrating lymphocytes (TILs) |
| 763 | Poster Presentation | Expanded and activated TILs kill tumor cells enabling IO compound assays | Paula Comune Pennacchi, PhD; Paloma Navarro; Verónica García Navas; Arántzazu Barquín García; Elena Sevillano Fernández; Sergio Ruiz Llorente; Juan Francisco Rodriguez; Monica Yagüe; Joan Ballesteros, PhD; Daniel Primo; Jesus Garcia Donas Jimenez; | Biomarkers, Immune Monitoring, and Novel Technologies | Bispecifics; Biomarkers; Checkpoint blockade; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
